pembrolizumab

Ligand id: 7499

Name: pembrolizumab

Immunopharmacology Comments
Included in GtoImmuPdb as it is an immune checkpoint inhibitor, not because it is a therapeutic for inflammatory conditions. Pembrolizumab is being evaluated in clinical trial in combination with anti-CD16A (FcγRIIIA) mAb AFM13 (a strategy aimed at maximising ADCC - see NCT02665650, Phase 1) for relapsed/refractory classical Hodgkin lymphoma.